<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809662</url>
  </required_header>
  <id_info>
    <org_study_id>1646493</org_study_id>
    <nct_id>NCT04809662</nct_id>
  </id_info>
  <brief_title>Comparing Immune Responses to Topical Imiquimod</brief_title>
  <official_title>Comparing Immune Responses to Topical Imiquimod</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a basic science research study that is designed to characterize and compare the&#xD;
      immune response in individuals who are designated as ABO blood group secretors, meaning they&#xD;
      have a functional copy of the FUT2 gene versus those patients who are designated ABO&#xD;
      non-secretors after application of topical imiquimod to these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response</measure>
    <time_frame>5 years</time_frame>
    <description>RNA sequencing of patients to gauge immune response as measured by expression of key inflammatory cytokines related to TLR7 response generated by imiquimod.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow cytometry</measure>
    <time_frame>3 years</time_frame>
    <description>Flow cytometry measurement of cell populations in patients after imiquimod</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemistry</measure>
    <time_frame>3 years</time_frame>
    <description>Immunohistochemical staining of patient biopsies using immune cell stains: CD3, CD4, CD8, CD68</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>Main cohort</arm_group_label>
    <description>This is a split-body study, with patients acting as their own controls between lesional and nonlesional skin. All patients will apply imiquimod.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for ~8 hours.&#xD;
(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied.</description>
    <arm_group_label>Main cohort</arm_group_label>
    <other_name>Aldara</other_name>
    <other_name>Zyclara</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who will use topical imiquimod as standard of care and who are without&#xD;
        immune-mediated systemic disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals between 18 to 85 years of age&#xD;
&#xD;
          -  Patients with a diagnosis that will result in treatment with imiquimod as standard of&#xD;
             care, specifically actinic keratosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Younger than 18 years or older than 85 years.&#xD;
&#xD;
          -  History of hypersensitivity/ allergic reaction or adverse reaction to imiquimod&#xD;
&#xD;
          -  Individuals with a diagnostic biopsy and supportive histology of a cutaneous&#xD;
             immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of&#xD;
             the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia,&#xD;
             Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis (PSC), Primary&#xD;
             Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).&#xD;
&#xD;
          -  Individuals with autoantibodies plus objective evidence of end organ damage related to&#xD;
             a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or&#xD;
             diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g.&#xD;
             aplastic anemia, Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis&#xD;
             (PSC), Primary Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).&#xD;
&#xD;
          -  Individuals with a history of serious infection within the last 6 months.&#xD;
&#xD;
          -  Individuals with tuberculosis, HIV, or hepatitis B, or C.&#xD;
&#xD;
          -  Patients unable to provide consent&#xD;
&#xD;
          -  Incarcerated individuals&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Downing</last_name>
      <phone>916-551-2635</phone>
      <email>ladowning@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>William Liakos</last_name>
      <phone>91655512630</phone>
      <email>wliakos@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Emanual Maverakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Emanual Maverakis, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>imiquimod</keyword>
  <keyword>aldara</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

